Upcoming results from 52 week RCT trials (DEPICT-2, inTandem1, inTandem2, Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients with Type 1 Diabetes Mellitus [EASE-2]) will help to determine whether SGLT inhibitor adjunct therapy has sustained benefits in terms of HbA1c, weight and total insulin dose reduction and determine its impact on rates of DKA and severe hypoglycaemia. Here, INS is linked to Hypoglycemia.